Details for Patent: 10,576,089
✉ Email this page to a colleague
Which drugs does patent 10,576,089 protect, and when does it expire?
Patent 10,576,089 protects KYZATREX and is included in one NDA.
This patent has twenty patent family members in eleven countries.
Summary for Patent: 10,576,089
| Title: | Modulation of solubility, stability, absorption, metabolism, and pharmacokinetic profile of lipophilic drugs by sterols |
| Abstract: | A formulation for drug delivery, providing enhanced modulation of solubility, stability, absorption, metabolism, and/or pharmacokinetic profile of a lipophilic therapeutic agent by formulation with sterols and/or sterol esters, resulting in higher bioavailability of a therapeutic agent administered to a subject in need of such therapeutic agent. The formulation contains a therapeutic agent and a sterol or sterol ester, and can, optionally, further contain a solubilizer and/or an enhancing agent. Also described are pharmaceutical compositions containing the formulations and methods of making and methods of using the formulations and pharmaceutical compositions. Formulations of the disclosure can be constituted to minimize the synthesis of dihydrotestosterone when the therapeutic agent includes testosterone or testosterone esters. |
| Inventor(s): | Dhingra; Om (Morrisville, NC) |
| Assignee: | Marius Pharmaceuticals LLC (Raleigh, NC) |
| Application Number: | 13/936,036 |
|
Patent Claim Types: see list of patent claims | Use; Formulation; Dosage form; |
Drugs Protected by US Patent 10,576,089
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Marius Pharms Llc | KYZATREX | testosterone undecanoate | CAPSULE;ORAL | 213953-001 | Jul 27, 2022 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | METHOD OF TREATING TESTOSTERONE DEFICIENCY | ⤷ Sign Up | |||
| Marius Pharms Llc | KYZATREX | testosterone undecanoate | CAPSULE;ORAL | 213953-002 | Jul 27, 2022 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | METHOD OF TREATING TESTOSTERONE DEFICIENCY | ⤷ Sign Up | |||
| Marius Pharms Llc | KYZATREX | testosterone undecanoate | CAPSULE;ORAL | 213953-003 | Jul 27, 2022 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | METHOD OF TREATING TESTOSTERONE DEFICIENCY | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 10,576,089
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Canada | 2822435 | ⤷ Sign Up | |||
| China | 105188670 | ⤷ Sign Up | |||
| European Patent Office | 2519230 | ⤷ Sign Up | |||
| European Patent Office | 2682111 | ⤷ Sign Up | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
